Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Issues Quarterly Earnings Results

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) announced its earnings results on Tuesday. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.10), Zacks reports. The firm had revenue of $10.96 billion for the quarter. Bayer Aktiengesellschaft had a negative net margin of 2.74% and a positive return on equity of 16.96%. Bayer Aktiengesellschaft updated its FY 2024 guidance to 5.610-6.045 EPS.

Bayer Aktiengesellschaft Price Performance

Shares of Bayer Aktiengesellschaft stock traded down $0.87 on Wednesday, hitting $5.58. 4,104,154 shares of the company traded hands, compared to its average volume of 1,120,233. The company has a current ratio of 1.27, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. Bayer Aktiengesellschaft has a 12-month low of $5.49 and a 12-month high of $11.33. The company has a 50-day moving average price of $7.44 and a 200 day moving average price of $7.43.

Analysts Set New Price Targets

Separately, Bank of America raised Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research report on Friday, September 6th. One equities research analyst has rated the stock with a sell rating and eight have issued a hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold”.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.